[Procognitive effects of fluvoxamine: preliminary data]. / Prokognitivnye éffekty fluvoksamina (predvaritel'nye dannye).

AIM: To identify and investigate procognitive effects of fluvoxamine. MATERIAL AND METHODS: A prospective non-comparative trial of fluvoxamine was carried out in 50 patients in the remission phase of recurrent depressive disorder. To assess the efficacy of therapy, the Stroop color and word test, the Revised version of Addenbrooke's Cognitive Examination, the Frontal Assessment Battery, the Hamilton Depression Scale and the Social Adaptation Self-Evaluation Scale were used. Fluvoxamine was administered at doses of 50-150 mg/day for 24-weeks. RESULTS: There were the improvement of executive functions, including selective attention and inhibitory control, and recovery of verbal fluency. The procognitive effect of fluvoxamine was dose-dependent and was related to the reduction of residual depressive symptoms. CONCLUSION: Fluvoxamine has procognitive effects, stabilizes remission and improves social adaptation of the patients.

[Cognitive impairment in depression and potential applications of antidepressants with procognitive effects]. / Kognitivnye narusheniia pri depressii i perspektivy primeneniia antidepressantov s prokognitivnym éffektom.

The characteristics of cognitive impairment in depression are reviewed. Data of literature indicate that cognitive impairment may serve as a predictor of depression recurrence and poor prognosis of antidepressant therapy. In this view, we consider the importance of assessment of cognitive impairment and differential use of medications with precognitive effect (bupropion, vorteoxetine and some SSRI antidepressants as well as fluvoxamine, which is a potent agonist of the sigma-1-receptor).

[Pantogam in the treatment of patients with organic brain lesions of different genesis].

We studied 35 patients with organic brain lesions caused by secondary brain harmful factors (group 1) and 33 patients with organic brain diseases of vascular genesis (group 2). Mean age of patients was 45.5±2.3 years. Asthenic, cerebroasthenic, psychoorganic syndromes in the combination with dissomnic, psychoautonomous, depressive, hypochondriac disorders predominated in the clinical picture of patients. Pantoham was prescribed in dose 1.0 g 3 times daily during 45 days. The effect of the drug on cognitive and mental disorders was found. The drug was most effective in patients of group 1. Pantoham was well-tolerated.